Navigation Links
TCT 2010 to have significant impact on interventional cardiology practices and patient care
Date:4/13/2010

NEW YORK, NY -- APRIL 13, 2010 TCT 2010 (Transcatheter Cardiovascular Therapeutics) will provide significant clinical research updates to technologies and practices in interventional cardiology that will directly affect patient care.

The important role of interventional cardiology has figured prominently in recent current events with the announcement that former President Clinton received a heart stent in February at New York-Presbyterian Hospital, followed by the reporting of clinical trial data showing promising results for a heart valve repair device that is inserted via a catheter.

At TCT 2010 (September 21-25 in Washington, DC), late breaking data from clinical trials on the next generation of stents, valve repair and replacement, and the interactions and effectiveness of new medicines will shed light on the best ways to treat patients.

"Catheter-based valve repair and replacement, novel stents, and the effectiveness of various drugs used to treat heart disease are going to be among the major topics at TCT this year," said Gregg W. Stone, MD, Professor of Medicine at Columbia University College of Physicians and Surgeons, Director of Cardiovascular Research and Education at the Center for Interventional Vascular Therapy at NewYork-Presbyterian Hospital/Columbia University Medical Center and Co-Director of the Medical Research and Education Division at the Cardiovascular Research Foundation. TCT is organized by the Cardiovascular Research Foundation.

"Non-surgical aortic valve replacement has the potential to be life saving for people who are at high risk for open heart surgery," Stone said. "As the population ages, this technique may dramatically benefit the quality of life for patients whose aortic valves (the valve through which blood passes from the heart to the rest of the body) fail to function properly. We are hopeful that new trial data that will be presented at TCT will usher in the field of non-operative aortic valve replacement."

This year, TCT will also provide a new program, "TCT in 3," designed specifically for the busy interventional practitioner, which features a concentrated curriculum in a shorter 3 day time frame from Thursday, September 23 through Saturday, September 25. Highlights include live cases, late breaking trials and practice management sessions.

And once again, the conference will feature specific tracks for Cardiac Surgeons and Nurses and Technologists. The Surgeons Course will provide instruction on percutaneous valve repair, hybrid (joint) surgical and interventional approaches to heart disease, percutaneous aortic aneurysm repair methods, with an in-depth course on advanced surgical techniques. The 19th Annual Nurse and Technologist Symposium will detail new trends and cath lab procedures essential for the allied health care professional.

In 2009, TCT was held for the first time in San Francisco, where it attracted record numbers of attendees. 99.4% of physician attendees surveyed stated that TCT increased their knowledge to improve their practice.


'/>"/>

Contact: Judy Romero
jromero@crf.org
212-851-9311
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. Sunquest Announces Significant Speaker Schedule for HIMSS 2010
2. Announcing New Book 'Ultimate Procrastination Cure', with a Significantly Different Approach to Stop Procrastinating
3. Mortality rates for pediatric rheumatology patients significantly lower than previously reported
4. Digital mammography delivers significantly less radiation than conventional mammography
5. Counterfeit Internet drugs pose significant risks and discourage vital health checks
6. Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders
7. Study finds significantly worse outcomes in cancer patients with cognitive impairment
8. New Actuarial Analysis Shows Senate Bill Would Significantly Raise Premiums
9. MyCareTeam™ Significantly Extends Diabetes Offering to Include Management of Hypertension, Obesity, and Congestive Heart Failure
10. Add Drama and Lift Spirits While Significantly Reducing Energy Cost; Peachtree Introduces the Evolution Series, LED, Energy Efficient Wall Sconce
11. Frost & Sullivan: E-Healthcare in Western Europe Presents a Significant Market Opportunity for Wireless Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are confused ... endometriosis. These women need a treatment plan to not only alleviate symptoms and ... help for preservation of fertility and ultimately achieving a pregnancy. The specialists at ...
(Date:6/25/2016)... ... 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to ... a new, often overlooked aspect of head lice: the parasite’s ability to live away from ... common occurrence, but a necessary one in the event that lice have simply gotten out ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... One of Australia,s successful biotechnology ... a new biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ... to list on the ASX. Noxopharm is a clinic-ready ... a Phase 1 clinical study later this year. ... the biggest problems facing cancer patients - the ability of cancers ...
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... Antitrust Improvements Act of 1976, as amended ("HSR"), with ... ("Celator"; Nasdaq: CPXX ) expired effective June ... As previously announced on May 31, 2016, Jazz ... under which Jazz Pharmaceuticals has commenced a tender offer ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
Breaking Medicine Technology: